Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP): 1 pipeline candidate · 5 upcoming catalysts · ~106 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
105.5 months
D/E 0.06 · 0% dilution
Lead: Phase 3
1 candidate
5 upcoming, next in ~377d
0 buys · 27 sells (180d)
A transparent, data-derived signal for Rapport Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$78.1M
Quarterly Burn
$13.1M
Runway
105.5 mo
Revenue
$20.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| rap-219 | Phase 3 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
144
Total value held
$1.41B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,168,939 | $224.3M |
| trv gp v, llc | 7,135,233 | $223.3M |
| arch venture management, llc | 3,728,738 | $116.7M |
| goldman sachs group inc | 2,942,251 | $92.1M |
| vanguard capital management llc | 2,650,164 | $82.9M |
| blackrock, inc. | 2,505,955 | $78.4M |
| johnson & johnson | 1,784,517 | $55.8M |
| polar capital holdings plc | 1,642,461 | $51.4M |
| baker bros. advisors lp | 1,547,090 | $48.4M |
| vestal point capital, lp | 1,436,229 | $44.9M |
Showing top 10 of 144 institutional holders of Rapport Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rapport Therapeutics, Inc.'s pipeline?
Rapport Therapeutics, Inc. (RAPP) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rapport Therapeutics, Inc.'s lead drug candidate?
Rapport Therapeutics, Inc.'s most advanced tracked candidate is rap-219 (Phase 3) for Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy.
What is Rapport Therapeutics, Inc.'s next catalyst?
Rapport Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: rap-219" — expected June 30, 2027.
What is Rapport Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rapport Therapeutics, Inc. has approximately 105.5 months of cash runway.
What is Rapport Therapeutics, Inc.'s market capitalization?
Rapport Therapeutics, Inc.'s market capitalization is approximately $1.8B.
Get the full picture on Rapport Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.